CD274 and cancer: The combination of PD-1/PD-L1 inhibitors with other therapies, such as chemoradiotherapy (CRT), other ICIs, cancer vaccines, and target drugs, was supposed to make the tumor more immunogenic, produce a synergistic effect, and gather stronger clinical benefit.